Big pharma Merck (MRK) was down nearly 2% on the stock market today after the latest data from its hepatitis C pipeline underwhelmed the Street. On Sunday at the annual conference of the American Association for the Study of Liver Disease, Merck reported the much-anticipated interim data from its C-Swift trial , which analysts thought could challenge market leader Gilead Sciences (GILD) if it could show high cure rates at four weeks to six weeks,
Gilead Sciences beat third-quarter sales estimates and issued cautious guidance late Tuesday, as its bottom line was hit by an ObamaCare-related fee. The stock slipped 4% after hours following a new record high during the regular session. Gilead (GILD) revenue rose 117% to $6.04 billion, beating analysts’ consensus by about $50 million. Earnings leapt 254% to $1.84 a share, but 8 cents short of the Street’s estimate. But Gilead said
Shares of Gilead Sciences (GILD) hit a new high near 113 in the stock market today as the biotech prepared to deliver its Q3 report after the close Tuesday, while an analyst noted that a couple of its potential competitors seemed to be faltering. Analysts polled by Thomson Reuters expect the company to report earnings of $1.92 a share, up 269% from the year-earlier quarter. Sales were estimated at just under $6 billion, up 115% from last year’s